Chapter 21 Expression of monoclonal antibody-defined lung tumour antigens in drug resistant lung tumour cell lines

[1]  J. Isbister,et al.  DETECTION OF A MULTIDRUG RESISTANT PHENOTYPE IN ACUTE NON-LYMPHOBLASTIC LEUKAEMIA , 1987, The Lancet.

[2]  N. Bleehen,et al.  Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. , 1986, British Journal of Cancer.

[3]  V. Ling,et al.  Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Riordan,et al.  Genetic and biochemical characterization of multidrug resistance. , 1985, Pharmacology & therapeutics.

[5]  M. Center,et al.  Involvement of plasma membrane lipid structural order in adriamycin resistance in Chinese hamster lung cells. , 1984, Cancer research.

[6]  T. Tritton,et al.  Adriamycin causes up regulation of epidermal growth factor receptors in actively growing cells. , 1983, Experimental cell research.

[7]  J. Minna,et al.  Monoclonal antibodies that distinguish non-small cell from small cell lung cancer. , 1983, Journal of immunology.

[8]  A. Sartorelli,et al.  Adriamycin-induced changes in the surface membrane of sarcoma 180 ascites cells. , 1981, Biochimica et biophysica acta.

[9]  F. L. Crane,et al.  Adriamycin affects plasma membrane redox functions. , 1980, Biochemical and biophysical research communications.

[10]  G. van Rossum,et al.  Inhibition of sodium-potassium-activated adenosine 5'-triphosphatase and ion transport by adriamycin. , 1979, Cancer research.

[11]  A. Sartorelli,et al.  Adriamycin: a proposal on the specificity of drug action. , 1978, Biochemical and biophysical research communications.